文献速递银屑病与炎症性皮肤病

阿那白滞素治疗掌跖脓疱病:随机双盲多中心两阶段适应性安慰剂对照试验(APRICOT)

Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT).
PubMed 文献 · Br J Dermatol · 2021-08-19

APRICOT试验纳入64例需系统治疗的掌跖脓疱病(PPP)患者,随机接受8周阿那白滞素或安慰剂皮下注射。结论认为IL-1阻断对PPP不是有效干预。

要点

  • 阿那白滞素8周治疗未显著改善PPPASI,未显示优于安慰剂。
  • 次要结局(脓疱计数、患者报告结局)亦未显示阿那白滞素优势。

核心结论

  • 未发现阿那白滞素优于安慰剂的证据,IL-1阻断不是治疗PPP的有效干预。

研究设计与样本

  • 随机(1:1)、双盲、两阶段、适应性、英国多中心、安慰剂对照试验(ISCRTN13127147;EudraCT 2015-003600-23)。
  • 干预为8周每日自行皮下注射阿那白滞素或安慰剂。

主要发现

  • 患者报告结局未显示阿那白滞素优效。
  • 未发生严重不良事件。

临床怎么用

  • 不推荐使用阿那白滞素治疗掌跖脓疱病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Palmoplantar pustulosis (PPP) is a rare, debilitating, chronic inflammatory skin disease that affects the hands and feet. Clinical, immunological and genetic findings suggest a pathogenic role for interleukin (IL)-1. OBJECTIVES: To determine whether anakinra (an IL-1 receptor antagonist) delivers therapeutic benefit in PPP. METHODS: This was a randomized (1 : 1), double-blind, two-staged, adaptive, UK multicentre, placebo-controlled trial [ISCRTN13127147 (registered 1 August 2016); EudraCT number: 2015-003600-23 (registered 1 April 2016)]. Participants had a diagnosis of PPP (> 6 months) requiring systemic therapy. Treatment was 8 weeks of anakinra or placebo via daily, self-administered subcutaneous injections. Primary outcome was the Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI) at 8 weeks. RESULTS: A total of 374 patients were screened; 64 were enrolled (31 in the anakinra arm and 33 in the placebo arm) with a mean (SD) baseline PPPASI of 17·8 (10·5) and a PPP investigator's global assessment of severe (50%) or moderate (50%). The baseline adjusted mean difference in PPPASI favoured anakinra but did not demonstrate superiority in the intention-to-treat analysis [-1·65, 95% confidence interval (CI) -4·77 to 1·47; P = 0·30]. Similarly, secondary objective measures, including fresh pustule count (2·94, 95% CI -26·44 to 32·33; favouring anakinra), total pustule count (-30·08, 95% CI -83·20 to 23·05; favouring placebo) and patient-reported outcomes, did not show superiority of anakinra. When modelling the impact of adherence, the PPPASI complier average causal effect for an individual who received ≥ 90% of the total treatment (48% in the anakinra group) was -3·80 (95% CI -10·76 to 3·16; P = 0·285). No serious adverse events occurred. CONCLUSIONS: No evidence for the superiority of anakinra was found. IL-1 blockade is not a useful intervention for the treatment of PPP.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Cro S, Cornelius VR, Pink AE, et al. Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT). Br J Dermatol. 2021. PMID: 34411292. doi:10.1111/bjd.20653

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。